CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial

MLA

Taro Goto, et al. “CYP2D6 Predicted Metabolizer Status and Safety in Adult Patients with Attention-Deficit Hyperactivity Disorder Participating in a Large Placebo-Controlled Atomoxetine Maintenance of Response Clinical Trial.” The Journal of Clinical Pharmacology, vol. 55, June 2015, pp. 1167–74. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........726614d027bdb7326f92f882caa5a92f&authtype=sso&custid=ns315887.

APA

Taro Goto, Yoko Tanaka, Himanshu P. Upadhyaya, Si G. Li, Bonnie Fijal, Yingying Guo, Laura Nisenbaum, & Jonna Ahl. (2015). CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. The Journal of Clinical Pharmacology, 55, 1167–1174.

Chicago

Taro Goto, Yoko Tanaka, Himanshu P. Upadhyaya, Si G. Li, Bonnie Fijal, Yingying Guo, Laura Nisenbaum, and Jonna Ahl. 2015. “CYP2D6 Predicted Metabolizer Status and Safety in Adult Patients with Attention-Deficit Hyperactivity Disorder Participating in a Large Placebo-Controlled Atomoxetine Maintenance of Response Clinical Trial.” The Journal of Clinical Pharmacology 55 (June): 1167–74. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........726614d027bdb7326f92f882caa5a92f&authtype=sso&custid=ns315887.